IL6 and diabetic cardiomyopathy: HQASM, on the basis of routine biomedicine medicine intervention, can reduce the levels of cTn-I, cTn-T, LDH and CK-MB in patients with diabetic cardiomyopathy and downregulate the levels of TGF-β1, MMP-2, IGF-1, IL-6, IL-1, TNF-α, NT-proBNP, sST2, and Gal-3, indicating that HQASM has anti-inflammatory and anti-MF effects in the treatment of DCM.